Evidence map›Paper›PMID 36249790›Full record

ArticleFrontiers in pharmacology2022

A nano-preparation approach to enable the delivery of daphnoretin to potentiate the therapeutical efficacy in hepatocellular cancer.

Guanglin Zhu, Bing Wang, Guo Feng, Zhirong Zhou, Wei Li, Wen Liu, Hongmei Su, Wenjing Wang, Tiejie Wang, Xie-An Yu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Guanglin ZhuDepartment of Chinese Materia Medica, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Bing WangNMPA Key Laboratory for Bioequivalence Research of Generic Drug Evaluation, Shenzhen Institute for Drug Control, Shenzhen, China.
Guo FengDepartment of Chinese Materia Medica, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Zhirong ZhouDepartment of Chinese Materia Medica, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Wei LiDepartment of Chinese Materia Medica, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Wen LiuDepartment of Chinese Materia Medica, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Hongmei SuDepartment of Chinese Materia Medica, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Wenjing WangDepartment of Chinese Materia Medica, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Tiejie WangNMPA Key Laboratory for Bioequivalence Research of Generic Drug Evaluation, Shenzhen Institute for Drug Control, Shenzhen, China.
Xie-An YuNMPA Key Laboratory for Bioequivalence Research of Generic Drug Evaluation, Shenzhen Institute for Drug Control, Shenzhen, China.
Guizhou University · CNShenzhen Institute for Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Daphnoretin (DAP), isolated from a traditional Chinese medicine

Indexed as

daphnoretinnano-preparationnatural producttargeting delivery system for the livertherapeutical efficacy in HCC

Identifiers

PMID36249790
PMCPMC9554561
OpenAlexW4297546390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.